by Team Small News | Nov 5, 2025 | Biocon, Pharma
The Biocon Group has successfully concluded its public interest campaign, #InvisibleYetImportant, which aimed to raise awareness about breast cancer and the importance of timely detection and regular screening. The campaign, which coincided with Breast Cancer... by Team Small News | Oct 27, 2025 | Biocon, Pharma
In a bid to address the concerns of industrialists over Bengaluru’s poor infrastructure, Deputy Chief Minister DK Shivakumar held a meeting with prominent business leaders, including Biocon founder Kiran Mazumdar-Shaw and former Infosys CFO Mohandas Pai. The... by Team Small News | Oct 24, 2025 | Biocon, Pharma
Biocon Biologics Ltd, a global biosimilars company, has announced that Health Canada has granted approval for Yesintek, a biosimilar to Stelara, for the treatment of several moderate to severe autoimmune diseases. The approval includes both subcutaneous and... by Team Small News | Oct 22, 2025 | Biocon, Pharma
Kiran Mazumdar-Shaw, the founder of Biocon, has defended her identity as a Kannadiga after facing backlash for her comments on Bengaluru’s infrastructure. In a recent post, she reaffirmed her love for the city and the Kannada culture, stating that she has spent... by Team Small News | Oct 13, 2025 | Biocon, Pharma
Biocon Ltd. has successfully completed a critical Good Manufacturing Practices (GMP) inspection by the US Food and Drug Administration (FDA) at its first manufacturing facility in the US, located in Cranbury, New Jersey. The inspection, which is mandatory for... by Team Small News | Oct 7, 2025 | Biocon, Pharma
Biocon, a biopharmaceutical company, has agreed to a settlement with Amgen, a multinational biotechnology company, regarding the biosimilars of Prolia and Xgeva. Prolia and Xgeva are two popular medications developed by Amgen, used to treat osteoporosis and prevent...